Abstract
2019 yeni koronavirüs hastalığı (COVID-19), ağır akut solunumsal sendrom koronavirüs (SARS-CoV-2) nedeniyle ortaya çıkmış, ilk kez Çin’in Wuhan eyaletinde bildirildikten sonra tüm dünyaya yayılarak etkisi altına almıştır. Yeni tip koronavirüs hastalığının klinik seyri sırasında baş ağrısı, yorgunluk ve nefes darlığı gibi semptomların yanı sıra ateş ve öksürük en sık görülen şikayetlerdir.
Literatürde astımlı hastalarda COVİD 19 izlemine ait sınırlı veri bulunmaktadır. Ayrıca günlük hayatımıza yeni giren bu hastalık hakkında dünya çapında rehber düzeyinde yeterli bilgi henüz mevcut değildir. Bu olgu sunumunda; astım ve COVİD 19tanısı olan, antiviral tedavi almamasına rağmen toraks tomografisi sekelsiz olarak iyileşen hastanın üç aylık klinik takibinin sunulması amaçlanmıştır.
Supporting Institution
bulunmamaktadır
Project Number
bulunmamaktadır
References
- CDCP. 2020. Centers for disease control and prevention. Coronavirus disease 2019 (COVID-19) situation summary. URL: https://www.cdc.gov/coronavirus/2019-ncov/ index.html (erişim tarihi: 15 Eylül 2020).
- Chen J. 2020. Pathogenicity and transmissibility of 2019-nCoV – A quick overview and comparison with other emerging viruses. MicrobesandInfection, 22(2): 69-71. DOI: 10.1016/j.micinf.2020.01.004.
- Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H. 2020b. Clinical and immunologic features in severe and moderate Coronavirus disease 2019. J Clin Invest, pii: 137244. DOI: 10.1172/JCI137244.
- Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J. 2020a. Analysis of clinical features of 29 patients with 2019 coronavirus pneumonia. ZhonghuaJie, 43(0): E005. DOI: 10.3760/cma.j.issn.1001-0939.2020.0005.
- Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. 2020. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med, 8(5): 436-438.
- Huang K, Yang T, Xu J2019. Prevalence, risk factors, andmanagement of asthma in China: a national cross-sectional study. Lancet, 394: 407-418.
- Sarıoğlu N. 2020. Asthmaand COVID-19: What do we know? Tuberk Toraks, 68(2): 141-147.
- Şener A. 2020. COVİD-19 (SARS Cov-2) Tedavisi. J Biotechnoland Strategic Health Res, 1 (Özel Sayı): 97-104.
- URL1: https://covid19.saglik.gov.tr/TR-66926/eriskin-hasta-tedavisi.html (erişim tarihi: 11.09.2020).
- Velavan TP, Meyer CG. 2020. The COVID-19 epidemic. Trop MedI nt Healt,. 25(3): 278-280. DOI: 10.1111/tmi.13383.
- Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S. 2020. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med, DOI: 10.1001/jamainternmed.2020.0994.
Three Months Follow-Up of a Patient with Asthma and COVID 19 Pneumonia Recovered Spontaneously without Antiviral Treatment
Abstract
2019 new coronavirus disease (COVID-19) has emerged due to severe acute respiratory syndrome coronavirus (SARS-CoV-2), after it was first reported in Wuhan province of China, it spread all over the world. During the clinical course of the new type of coronavirus disease, symptoms can detected such as headache, fatigue and shortness of breath are the most commons, as well as fever and cough. There is limited data in the literature regarding the follow-up of COVID 19 in asthmatic patients. In addition, there is not enough information about this disease, which has recently entered our daily life, at the level of guidance worldwide. In this case report; It is aimed to present a three-month clinical follow-up of the patient who was diagnosed with asthma and COVID 19 and recovered without any sequelae on thoracic tomography despite not receiving antiviral therapy.
Project Number
bulunmamaktadır
References
- CDCP. 2020. Centers for disease control and prevention. Coronavirus disease 2019 (COVID-19) situation summary. URL: https://www.cdc.gov/coronavirus/2019-ncov/ index.html (erişim tarihi: 15 Eylül 2020).
- Chen J. 2020. Pathogenicity and transmissibility of 2019-nCoV – A quick overview and comparison with other emerging viruses. MicrobesandInfection, 22(2): 69-71. DOI: 10.1016/j.micinf.2020.01.004.
- Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H. 2020b. Clinical and immunologic features in severe and moderate Coronavirus disease 2019. J Clin Invest, pii: 137244. DOI: 10.1172/JCI137244.
- Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J. 2020a. Analysis of clinical features of 29 patients with 2019 coronavirus pneumonia. ZhonghuaJie, 43(0): E005. DOI: 10.3760/cma.j.issn.1001-0939.2020.0005.
- Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. 2020. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med, 8(5): 436-438.
- Huang K, Yang T, Xu J2019. Prevalence, risk factors, andmanagement of asthma in China: a national cross-sectional study. Lancet, 394: 407-418.
- Sarıoğlu N. 2020. Asthmaand COVID-19: What do we know? Tuberk Toraks, 68(2): 141-147.
- Şener A. 2020. COVİD-19 (SARS Cov-2) Tedavisi. J Biotechnoland Strategic Health Res, 1 (Özel Sayı): 97-104.
- URL1: https://covid19.saglik.gov.tr/TR-66926/eriskin-hasta-tedavisi.html (erişim tarihi: 11.09.2020).
- Velavan TP, Meyer CG. 2020. The COVID-19 epidemic. Trop MedI nt Healt,. 25(3): 278-280. DOI: 10.1111/tmi.13383.
- Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S. 2020. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med, DOI: 10.1001/jamainternmed.2020.0994.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Internal Diseases |
| Journal Section | Case Report |
| Authors | |
| Project Number | bulunmamaktadır |
| Publication Date | May 1, 2021 |
| Submission Date | September 17, 2020 |
| Acceptance Date | November 25, 2020 |
| Published in Issue | Year 2021 |